Developed as a therapeutic for neuropathic pain, iQ-008 shows significant effects in all pain models.
iQ-008 delivers demonstrable efficacy after oral dosing
DELAWARE, March 10, 2022 ─ iQure Pharma Inc. (iQure), a biotech company, has confirmed through preclinical screenings that iQ-008, a novel analgesic compound, demonstrates efficacy in in vivo studies. Developed as a therapeutic for neuropathic pain, iQ-008 shows significant effects in all pain models.
A rationally designed, multi-targeting compound, iQ-008 presented a better-than-standard profile in preclinical efficacy screenings. “This is very good news and an important step in the development of iQ-008 as a promising therapeutic,” said iQure Chief Executive Officer Pawel Zolnierczyk. “The results of efficacy after oral dosing are a further indication that iQ-008 will be viable in capsule or tablet form in human studies. We are encouraged for successful in vivo studies by the data confirming that iQ-008 meets the Lipinski/Pfizer Rule of Five,” he added.
Lipinski’s Rule of Five, also known as Pfizer’s Rule of Five, is a critical filter for drug development programs that helps identify successful drug candidates. The rules identify candidates likely to have a desired profile on intestinal permeability and aqueous solubility, which is an indication for oral absorption.
Earlier this year, iQure decided to secure global protection (including the US, Europe, China and Canada) for iQ-008, following results showing efficacy in outperforming standards of care.
About iQure Pharma
As a global biotech firm headquartered in the US, iQure Pharma is focused on the development of new therapeutics for neuropathic pain. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information or to support iQure’s initiatives, contact iQure CFO Dr. Anna Rzewuska at anna.rzewuska@iqurepharma.com